Literature DB >> 3387499

Plasma homovanillic acid levels and subtyping of schizophrenia.

W H Chang1, T Y Chen, C F Lee, J C Hung, W H Hu, E K Yeh.   

Abstract

Plasma levels of homovanillic acid (HVA), a major metabolite of dopamine, were measured in a group of 24 schizophrenic inpatients before and during 6 weeks of haloperidol (HAL) treatment. Steady-state plasma HAL levels were measured in parallel with plasma HVA. Differential plasma HVA responses to HAL treatment were found between good and poor outcome patients. The two groups did not differ significantly in plasma HAL levels. Two hypothetical subtypes of schizophrenia are proposed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3387499     DOI: 10.1016/0165-1781(88)90014-5

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  9 in total

1.  Double blind comparative study of remoxipride and haloperidol in acute schizophrenic patients.

Authors:  J A Den Boer; D P Ravelli; J Huisman; J Ohrvik; W M Verhoeven; H G Westenberg
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

2.  Negative symptoms in nondeficit syndrome respond to neuroleptic treatment with changes in plasma homovanillic acid concentrations.

Authors:  E Suzuki; S Kanba; H Koshikawa; M Nibuya; G Yagi; M Asai
Journal:  J Psychiatry Neurosci       Date:  1996-05       Impact factor: 6.186

3.  Monoamine activity reflected in urine of young patients with obsessive compulsive disorder, psychosis with and without reality distortion and healthy subjects: an explorative analysis.

Authors:  R D Oades; B Röpcke; C Eggers
Journal:  J Neural Transm Gen Sect       Date:  1994

4.  Persistent psychosis after reduction in pre- and post-synaptic dopaminergic function.

Authors:  A Wolkin; E Duncan; M Sanfilipo; S Wieland; T B Cooper; J Rotrosen
Journal:  J Neural Transm Gen Sect       Date:  1994

5.  Relationships between clinical effects and monoamine metabolites and amino acids in sulpiride-treated schizophrenic patients.

Authors:  G Alfredsson; F A Wiesel
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 6.  Pharmacokinetics of haloperidol.

Authors:  J S Froemming; Y W Lam; M W Jann; C M Davis
Journal:  Clin Pharmacokinet       Date:  1989-12       Impact factor: 6.447

7.  Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment.

Authors:  G Alfredsson; F A Wiesel
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

8.  Heterogeneity in plasma homovanillic Acid levels in schizophreniform disorder.

Authors:  N Pradhan; C Harihar; P Das; C Andrade
Journal:  Indian J Psychiatry       Date:  1992-04       Impact factor: 1.759

9.  Antidopaminergic medication in healthy subjects provokes subjective and objective mental impairments tightly correlated with perturbation of biogenic monoamine metabolism and prolactin secretion.

Authors:  Tanja Veselinović; Ingo Vernaleken; Paul Cumming; Uwe Henning; Lina Winkler; Peter Kaleta; Michael Paulzen; Christian Luckhaus; Gerhard Gründer
Journal:  Neuropsychiatr Dis Treat       Date:  2018-04-27       Impact factor: 2.570

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.